Since a reduced LDL/HDL ratio has been observed in ALS patients, treatment with ApoA1 might increase HDL-mediated removal of cholesterol from cells and improve the cholesterol efflux process [reviewed in Cochran et al. (2021), and Bhale and Venkataraman (2022)]. Here, APOA1 is linked to amyotrophic lateral sclerosis.